S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:APLT

Applied Therapeutics Stock Forecast, Price & News

$10.88
-0.23 (-2.07%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.55
$11.14
50-Day Range
$10.81
$18.29
52-Week Range
$10.22
$29.80
Volume
73,455 shs
Average Volume
101,626 shs
Market Capitalization
$285.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.92
30 days | 90 days | 365 days | Advanced Chart
Receive APLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Applied Therapeutics logo

About Applied Therapeutics

Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Headlines

Is Applied Therapeutics (NASDAQ:APLT) Using Debt Sensibly?
September 17, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APLT
Fax
N/A
Employees
24
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$3.31 per share

Profitability

Net Income
$-93.96 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
19,085,000
Market Cap
$285.23 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/12/2021
Today
11/27/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/17/2022

MarketRank

Overall MarketRank

2.36 out of 5 stars

Medical Sector

216th out of 1,392 stocks

Pharmaceutical Preparations Industry

94th out of 670 stocks

Analyst Opinion: 3.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -












Applied Therapeutics (NASDAQ:APLT) Frequently Asked Questions

Is Applied Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Applied Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APLT, but not buy additional shares or sell existing shares.
View analyst ratings for Applied Therapeutics
or view top-rated stocks.

How has Applied Therapeutics' stock been impacted by Coronavirus?

Applied Therapeutics' stock was trading at $29.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APLT stock has decreased by 63.2% and is now trading at $10.88.
View which stocks have been most impacted by COVID-19
.

When is Applied Therapeutics' next earnings date?

Applied Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Applied Therapeutics
.

How were Applied Therapeutics' earnings last quarter?

Applied Therapeutics, Inc. (NASDAQ:APLT) released its quarterly earnings results on Friday, November, 12th. The company reported ($1.09) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.15) by $0.06.
View Applied Therapeutics' earnings history
.

What price target have analysts set for APLT?

2 Wall Street analysts have issued 12 month target prices for Applied Therapeutics' shares. Their forecasts range from $10.00 to $35.00. On average, they expect Applied Therapeutics' stock price to reach $22.50 in the next twelve months. This suggests a possible upside of 106.8% from the stock's current price.
View analysts' price targets for Applied Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Applied Therapeutics' key executives?

Applied Therapeutics' management team includes the following people:

What other stocks do shareholders of Applied Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS) and Raytheon Technologies (RTX).

When did Applied Therapeutics IPO?

(APLT) raised $60 million in an IPO on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager.

What is Applied Therapeutics' stock symbol?

Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."

Who are Applied Therapeutics' major shareholders?

Applied Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (4.94%), Point72 Asset Management L.P. (3.88%), Franklin Resources Inc. (3.19%), Emerald Mutual Fund Advisers Trust (2.37%), Emerald Advisers LLC (2.16%) and Geode Capital Management LLC (1.21%). Company insiders that own Applied Therapeutics stock include Charles Silberstein, Joel S Marcus, Leslie D Funtleyder, Real Estate Equitie Alexandria, Riccardo Perfetti, Shoshana Shendelman and Stacy J Kanter.
View institutional ownership trends for Applied Therapeutics
.

Which major investors are selling Applied Therapeutics stock?

APLT stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, BlackRock Inc., Voya Investment Management LLC, New York State Common Retirement Fund, Emerald Advisers LLC, UBS Group AG, and California State Teachers Retirement System. Company insiders that have sold Applied Therapeutics company stock in the last year include Charles Silberstein, and Riccardo Perfetti.
View insider buying and selling activity for Applied Therapeutics
or view top insider-selling stocks.

Which major investors are buying Applied Therapeutics stock?

APLT stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Dimensional Fund Advisors LP, Geode Capital Management LLC, Two Sigma Investments LP, Barclays PLC, Deutsche Bank AG, Millennium Management LLC, and Squarepoint Ops LLC. Company insiders that have bought Applied Therapeutics stock in the last two years include Real Estate Equitie Alexandria, Shoshana Shendelman, and Stacy J Kanter.
View insider buying and selling activity for Applied Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Applied Therapeutics?

Shares of APLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Applied Therapeutics' stock price today?

One share of APLT stock can currently be purchased for approximately $10.88.

How much money does Applied Therapeutics make?

Applied Therapeutics has a market capitalization of $285.23 million. The company earns $-93.96 million in net income (profit) each year or ($4.14) on an earnings per share basis.

How many employees does Applied Therapeutics have?

Applied Therapeutics employs 24 workers across the globe.

What is Applied Therapeutics' official website?

The official website for Applied Therapeutics is www.appliedtherapeutics.com.

Where are Applied Therapeutics' headquarters?

Applied Therapeutics is headquartered at 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173.

How can I contact Applied Therapeutics?

Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company can be reached via phone at (212) 220-9226 or via email at [email protected].


This page was last updated on 11/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.